Offering You Practical Solutions With Outstanding Results 

Pharmaceutical and biotech companies are challenged by more complex supply chains, ever-changing regulations and a volatile and uncertain global environment where patients and healthcare providers expect affordable, high quality medicines.

At NSF we have over 30 years’ industry experience. We have all stood in your shoes and understand your challenges. Scroll down to learn more about the services we provide.

About NSF: Global Experts for Pharmaceutical Consulting, Auditing and Training 

Contact us if you want to be proactive and drive improvements, or if you have some specific regulatory or technical issues and need guidance. We offer the following services:

  • Development and implementation of cost-effective, compliant pharmaceutical quality systems
  • Advice on design, qualification and validation of new facilities, equipment, computerized systems and processes
  • Legal and regulatory issue guidance
  • Assistance with responses to regulatory inspection reports
  • Simplification of quality processes, SOPs and batch records
  • Advice on specific technical problems
  • Benchmarking against best industry practices – beyond the regulations

Learn more about our range of services.

Standards

NSF perform audits against Good Manufacturing Practice, Good Distribution Practice, Good Pharmacovigilance Practice and Good Clinical Practice international regulations.

Audits

We audit active pharmaceutical ingredients, excipients, medicinal product manufacturers, distributors, investigational medicinal product manufacturers, QC laboratories, affiliates, contract manufacturers, computerized systems and more.

Our processes can be tailored to your specific needs, including:

  • Due diligence audits
  • Compliance auditing – assessment of activities against standards
  • Inspection readiness audits
  • Auditing your supplier
  • Audits of your internal audit processes

Outputs can include efficiently reaching compliance.

Learn more about our range of services.

You are only as good as your people. We offer education programs that will change behaviors, improve performance and “future proof” your organization. Any of our European public courses can be tailored and run on-site globally. Examples of education offered annually include:

  • Good manufacturing practice, including clinical trials
  • Regulatory issues and regulatory affairs
  • Auditing and self-inspections (Including a CQI and IRCA certified course)
  • Sterile and biotech products manufacture
  • Quality risk management
  • Human error prevention
  • Changing GMP behaviors
  • Data integrity
  • Process validation
  • Deviation and CAPA Management
  • Responsible person and Good Distribution Practice

We also work alongside the University of Strathclyde to provide a Royal Society of Chemistry Approved Qualified Person training program.


Learn more about our pharmaceutical training.

Looking for an update on the health sciences industry? NSF’s Health Sciences Journal provides you with the latest industry insights on current hot topics as well as essential tips, advice and knowledge from our team of experts which includes former regulatory agency staff and experienced industry professionals. You will also receive the latest global regulatory updates and details of our training and education program.

View our latest Journal.

Get the latest updates on the health sciences industry - sign up for NSF’s Journal.

Go to article: Home | The power of patientsGo to article: Scandinavian Health Company InsightGo to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: CapsugelGo to article: Capsugel Company Insight Go to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: Molnar Company InsightGo to article: Molnar-InstituteGo to article: A costly oversight: the ongoing impact of the valsartan recallGo to article: Novo Nordisk Company InsightGo to article: Novo NordiskGo to article: Where is the UK’s supply of Migraleve?Go to article: Dupont PharmaceuticalsGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Charting the life and times of the EMA as it leaves LondonGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: CBD: the myth, the magic and the real deal drugsGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: How do cancer cells communicate and can it help us catch them?Go to article: HOF SonderanlagenbauGo to article: HOF Sonderanlagenbau Company Insight Go to article: Buyers’ clubs: the first step toward universal UK access to Orkambi?Go to article: SterigenicsGo to article: Owen MumfordGo to article: Are we nearing the end of animal testing in pharma?Go to article: Zenatek Go to article: Barc Lab Go to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Abiogen PharmaGo to article: MimotopesGo to article: Next issue